Background. A prior study to evaluate the safety and efficacy of ceftaroline vs vancomycin plus aztreonam in SSTI demonstrated that clinical cure rates were similar for ceftaroline compared with vancomycin plus aztreonam. The majority of the patient population in the study had Body Mass Index (BMI) < 30. There is very little data on the efficacy of ceftaroline in patients with BMI>30. We conducted a study to compare the efficacy and safety of ceftaroline in a population with normal BMI compared with those with BMI > 30.
A prior study to evaluate the safety and efficacy of ceftaroline vs vancomycin plus aztreonam in SSTI demonstrated that clinical cure rates were similar for ceftaroline compared with vancomycin plus aztreonam. The majority of the patient population in the study had Body Mass Index (BMI) < 30. There is very little data on the efficacy of ceftaroline in patients with BMI>30. We conducted a study to compare the efficacy and safety of ceftaroline in a population with normal BMI compared with those with BMI > 30.
Methods. Retrospective study of patients admitted to Vidant Medical Center from May to September of 2013 with the diagnosis of SSTI and who were treated with ceftaroline. Patients' BMIs were calculated, and duration of treatment and adverse effects were noted. We also examined vancomycin use in patients with SSTI from May to September of 2011 and 2012 in order to compare the efficacy and safety between vancomycin and ceftaroline. Student's t-test and Fisher's exact test were used to assess differences in categorical values. P values <0.05 were considered statistically significant.
Results. Of total 244 patients, 134 received ceftaroline and 110 received vancomycin with or without gram-negative coverage therapy. Baseline characteristics of the treatment groups were comparable. Among 134 patients in the ceftaroline group, 84 patients (62.7%) had BMI > 30. Clinical improvement were similar between patients with BMI<30 and BMI>30 (96% vs 95.2%). Among 110 patients treated with vancomycin, there were 85 patients (77.3%) with BMI > 30. When compared with vancomycin in patients with BMI > 30, clinical cure rate was similar for those treated with ceftaroline (95.2% vs 97.6%). However, there was a higher rate of acute kidney injury in patients with BMI > 30 who were treated with vancomycin (7.06% vs 0%, p = 0.028).
Conclusion. Ceftaroline therapy was associated with similar clinical cure rates in both normal (BMI <30) as well as among obese (BMI>30) patients when compared with vancomycin with or without gram-negative coverage combination therapy. The medication was well tolerated and had minimal side effects in all patients. In obese patients, vancomycin was associated with a higher incidence of acute renal injury as compared with ceftaroline.
Disclosures. P. Cook, Gilead (investigator), Pfizer (investigator), Merck (investigator and speakers' bureau, Forest (Speaker honorarium)
